<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d304" origId="Botulinum Toxin Type B"><sentence id="DrugDDI.d304.s0" origId="s0" text="Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated."><entity id="DrugDDI.d304.s0.e0" origId="s0.p1" charOffset="21-28" type="drug" text="MYOBLOC"/><entity id="DrugDDI.d304.s0.e1" origId="s0.p3" charOffset="33-48" type="drug" text="aminoglycosides"/><entity id="DrugDDI.d304.s0.e2" origId="s0.p10" charOffset="116-122" type="drug" text="curare"/><entity id="DrugDDI.d304.s0.e3" origId="s0.p19" charOffset="198-203" type="drug" text="toxin"/><pair id="DrugDDI.d304.s0.p0" e1="DrugDDI.d304.s0.e0" e2="DrugDDI.d304.s0.e1" interaction="true"/><pair id="DrugDDI.d304.s0.p1" e1="DrugDDI.d304.s0.e0" e2="DrugDDI.d304.s0.e2" interaction="false"/><pair id="DrugDDI.d304.s0.p2" e1="DrugDDI.d304.s0.e0" e2="DrugDDI.d304.s0.e3" interaction="false"/><pair id="DrugDDI.d304.s0.p3" e1="DrugDDI.d304.s0.e1" e2="DrugDDI.d304.s0.e2" interaction="false"/><pair id="DrugDDI.d304.s0.p4" e1="DrugDDI.d304.s0.e1" e2="DrugDDI.d304.s0.e3" interaction="false"/><pair id="DrugDDI.d304.s0.p5" e1="DrugDDI.d304.s0.e2" e2="DrugDDI.d304.s0.e3" interaction="false"/></sentence><sentence id="DrugDDI.d304.s1" origId="s1" text="The effect of administering different botulinum neurotoxin serotypes at the same time or within less than 4 months of each other is unknown."><entity id="DrugDDI.d304.s1.e0" origId="s1.p24" charOffset="38-58" type="drug" text="botulinum neurotoxin"/></sentence><sentence id="DrugDDI.d304.s2" origId="s2" text="However, neuromuscular paralysis may be potentiated by co-administration or overlapping administration of different botulinum toxin serotypes."><entity id="DrugDDI.d304.s2.e0" origId="s2.p40" charOffset="116-142" type="drug" text="botulinum toxin serotypes"/></sentence></document>